ATE500808T1 - Onkolytische virustherapie - Google Patents
Onkolytische virustherapieInfo
- Publication number
- ATE500808T1 ATE500808T1 AT02725980T AT02725980T ATE500808T1 AT E500808 T1 ATE500808 T1 AT E500808T1 AT 02725980 T AT02725980 T AT 02725980T AT 02725980 T AT02725980 T AT 02725980T AT E500808 T1 ATE500808 T1 AT E500808T1
- Authority
- AT
- Austria
- Prior art keywords
- oncolytic virus
- pharmaceutical composition
- virus therapy
- subject
- human leukocytes
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 210000000265 leukocyte Anatomy 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29005101P | 2001-05-11 | 2001-05-11 | |
| PCT/US2002/014642 WO2002091997A2 (en) | 2001-05-11 | 2002-05-09 | Oncolytic virus therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500808T1 true ATE500808T1 (de) | 2011-03-15 |
Family
ID=23114328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02725980T ATE500808T1 (de) | 2001-05-11 | 2002-05-09 | Onkolytische virustherapie |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7122182B2 (de) |
| EP (1) | EP1385466B1 (de) |
| JP (1) | JP4916641B2 (de) |
| CN (1) | CN1332712C (de) |
| AT (1) | ATE500808T1 (de) |
| AU (1) | AU2002256510B2 (de) |
| CA (1) | CA2442648C (de) |
| DE (1) | DE60239394D1 (de) |
| HU (1) | HUP0400882A3 (de) |
| IL (1) | IL157504A0 (de) |
| MX (1) | MXPA03010278A (de) |
| NZ (1) | NZ527687A (de) |
| WO (1) | WO2002091997A2 (de) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 | |
| AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
| NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
| IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
| US7615209B2 (en) * | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
| AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
| US20050214266A1 (en) * | 2004-03-12 | 2005-09-29 | Oncolytics Biotech Inc. | Combination of transplantation and oncolytic virus treatment |
| KR101295733B1 (ko) * | 2004-08-20 | 2013-08-13 | 비랄리틱스 리미티드 | 혈액암의 치료방법 및 조성물 |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
| US20070077231A1 (en) | 2005-09-30 | 2007-04-05 | Contag Christopher H | Immune effector cells pre-infected with oncolytic virus |
| US20100086522A1 (en) * | 2006-07-18 | 2010-04-08 | Ottawa Health Research Institute | Disparate suicide carrier cells for tumor targeting of promiscuous oncolytic viruses |
| US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
| US9241998B2 (en) * | 2007-05-21 | 2016-01-26 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oncolytic RSV activity |
| CA2706750A1 (en) * | 2007-11-27 | 2009-06-04 | Ottawa Health Research Institute | Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors |
| WO2010020247A1 (en) * | 2008-08-22 | 2010-02-25 | Reapplix Aps | Multilayered blood product |
| US8481297B2 (en) * | 2009-01-08 | 2013-07-09 | Yale University | Compositions and methods of use of an oncolytic vesicular stomatitis virus |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| CA2689707A1 (en) | 2009-11-16 | 2011-05-16 | Jean-Simon Diallo | Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening |
| EP2764119A2 (de) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Methoden zum nachweis der replikation oder kolonisierung eines biologischen therapiemittels |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| SI3250550T1 (sl) | 2015-01-26 | 2023-08-31 | Ottawa Hospital Research Institute | Sestave in metode za senzibilizacijo virusov |
| GB201504251D0 (en) | 2015-03-13 | 2015-04-29 | Virttu Biolog Ltd And University Of Sheffield The | Oncolytic herpes simplex virus infected cells |
| HK1248588A1 (zh) | 2015-08-11 | 2018-10-19 | Calidi Biotherapeutics, Inc. | 用於癌症治疗中的天花疫苗 |
| JP6933652B2 (ja) | 2016-01-06 | 2021-09-08 | リアプリックス エーピーエス | 後続の自己使用に適した凝固促進因子 |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (de) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155-variante immunmodulatorische proteine und verwendungen davon |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| CN110022889B (zh) | 2016-10-03 | 2024-05-10 | 渥太华医院研究所 | 用于提高溶瘤rna病毒的生长、传播和溶瘤与免疫治疗效果的组合物和方法 |
| EP3872180A1 (de) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Sekretierbare variante immunmodulatorische proteine und manipulierte zelltherapie |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| FI3596116T3 (fi) | 2017-03-16 | 2023-11-09 | Alpine Immune Sciences Inc | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Pd−l2バリアント免疫調節タンパク質及びその使用 |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントicosリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| CA3079100C (en) | 2017-11-24 | 2023-09-19 | Ottawa Hospital Research Institute | Compositions and methods for enhancing production, growth, spread, or oncolytic and immunotherapeutic efficacy of interferon-sensitive viruses |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| EP3884041A2 (de) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Verfahren zur expansion des subsets von natürlichen killer (nk)-tellen und verwandte zusammensetzungen und verfahren |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(nk) 세포 조성물 및 이를 생성하는 방법 |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| CN117379389B (zh) * | 2022-07-12 | 2026-03-06 | 四川大学 | 血小板-溶瘤病毒复合物、其制备方法及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126132A (en) | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
| ES2310580T3 (es) * | 1993-04-30 | 2009-01-16 | Wellstat Biologics Corporation | Composiciones purificadas del virus de la enfermedad de newcastle. |
| US5595739A (en) * | 1993-05-07 | 1997-01-21 | Abbott Laboratories | Hepatitis B virus mutants, reagents and methods for detection |
| US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| ATE229810T1 (de) * | 1996-10-11 | 2003-01-15 | Univ California | Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen |
| EP1905304A3 (de) | 1997-10-09 | 2008-08-13 | Wellstat Biologics Corporation | Behandlung von Neoplasmen mit Viren |
| WO1999029343A1 (en) * | 1997-12-09 | 1999-06-17 | Thomas Jefferson University | Method of treating bladder cancer with wild type vaccinia virus |
| EP1061806A4 (de) * | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | Produktive zellen für replikationsselektive viren zur behandlung bösartiger erkrankungen |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 | |
| JP3639772B2 (ja) * | 1999-06-30 | 2005-04-20 | キヤノン株式会社 | 情報処理装置および印刷システムおよび印刷制御方法およびコンピュータが読み出し可能なプログラムを格納した記憶媒体 |
| AU782402B2 (en) | 1999-09-17 | 2005-07-28 | Wellstat Biologics Corporation | Oncolytic virus |
| US6270147B1 (en) * | 2000-01-07 | 2001-08-07 | Daimlerchrysler Corporation | Drive arrangement for a power liftgate including clutching mechanism |
| WO2002000233A2 (en) * | 2000-06-26 | 2002-01-03 | Wellstat Biologics Corporation | Purging of cells using viruses |
| NZ527687A (en) * | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
-
2002
- 2002-05-09 NZ NZ527687A patent/NZ527687A/en not_active IP Right Cessation
- 2002-05-09 US US10/142,405 patent/US7122182B2/en not_active Expired - Fee Related
- 2002-05-09 AT AT02725980T patent/ATE500808T1/de not_active IP Right Cessation
- 2002-05-09 EP EP02725980A patent/EP1385466B1/de not_active Expired - Lifetime
- 2002-05-09 HU HU0400882A patent/HUP0400882A3/hu unknown
- 2002-05-09 CA CA2442648A patent/CA2442648C/en not_active Expired - Fee Related
- 2002-05-09 MX MXPA03010278A patent/MXPA03010278A/es active IP Right Grant
- 2002-05-09 WO PCT/US2002/014642 patent/WO2002091997A2/en not_active Ceased
- 2002-05-09 CN CNB028097009A patent/CN1332712C/zh not_active Expired - Fee Related
- 2002-05-09 IL IL15750402A patent/IL157504A0/xx not_active IP Right Cessation
- 2002-05-09 DE DE60239394T patent/DE60239394D1/de not_active Expired - Lifetime
- 2002-05-09 JP JP2002588916A patent/JP4916641B2/ja not_active Expired - Fee Related
- 2002-05-09 AU AU2002256510A patent/AU2002256510B2/en not_active Ceased
-
2005
- 2005-05-05 US US11/122,690 patent/US7595042B2/en not_active Expired - Fee Related
-
2009
- 2009-03-26 US US12/412,035 patent/US8137663B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002091997A2 (en) | 2002-11-21 |
| CN1514688A (zh) | 2004-07-21 |
| AU2002256510B2 (en) | 2007-08-30 |
| EP1385466B1 (de) | 2011-03-09 |
| EP1385466A4 (de) | 2005-10-12 |
| CA2442648A1 (en) | 2002-11-21 |
| NZ527687A (en) | 2005-10-28 |
| US8137663B2 (en) | 2012-03-20 |
| DE60239394D1 (de) | 2011-04-21 |
| CA2442648C (en) | 2012-10-16 |
| JP4916641B2 (ja) | 2012-04-18 |
| CN1332712C (zh) | 2007-08-22 |
| US20090180994A1 (en) | 2009-07-16 |
| MXPA03010278A (es) | 2004-12-06 |
| JP2004521938A (ja) | 2004-07-22 |
| US7595042B2 (en) | 2009-09-29 |
| WO2002091997A3 (en) | 2003-03-13 |
| HUP0400882A2 (hu) | 2004-07-28 |
| US7122182B2 (en) | 2006-10-17 |
| US20030077819A1 (en) | 2003-04-24 |
| EP1385466A2 (de) | 2004-02-04 |
| US20050208024A1 (en) | 2005-09-22 |
| HUP0400882A3 (en) | 2011-01-28 |
| IL157504A0 (en) | 2004-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60239394D1 (de) | Onkolytische virustherapie | |
| NO20026044D0 (no) | Behandling av human papillomavirus | |
| ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
| BR9912653A (pt) | Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal | |
| DE60041210D1 (de) | Onkolytisches Virus | |
| DK184186A (da) | Terapeutisk praeparat til behandling af virussygdomme | |
| MY117892A (en) | Therapeutic compounds | |
| TR200001891T2 (tr) | ASPB28- İnsan ensülini ve kullanımı. | |
| CY1106152T1 (el) | Νεα ανοσογονα αντι-hiv (ανατοξινες), μεθοδοι παρασκευης και εφαρμογη στην προληψη και στην αγωγη του aids | |
| CY1105818T1 (el) | Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου | |
| GEP20053504B (en) | Low Dose Entecavir Pharmaceutical Composition and Use Thereof for Treatment of Hepatitis B | |
| AP9801286A0 (en) | Therapeutic compounds. | |
| MD990258A (en) | Method of treatment of the acute viral hepatitis B | |
| BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
| MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
| ATE185274T1 (de) | Therapeutisches mittel gegen drohenden abortus | |
| ATE345805T1 (de) | Calciumtrifluoracetat mit zytotoxischer wirkung | |
| EA199800770A1 (ru) | Лекарственный препарат для терапевтического лечения вирусного гепатита | |
| WO2001070951A3 (de) | Mittel zur diagnose und therapie viraler erkrankungen | |
| DE69925312D1 (de) | Bupropion zur behandlung von viralen erkrankungen | |
| DK1150981T3 (da) | Terapeutisk necleosidforbindelse | |
| DE69803052D1 (de) | Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt | |
| TW200513258A (en) | Auxiliary agent for hepatitis C | |
| SU1565027A1 (ru) | Инактиватор вируса западного нила | |
| ITAG940002A0 (it) | Apparecchio ossigenatore e purificatore del sangue infetto da virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |